Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Not Recruiting

Trial ID: NCT02596997

Age - 2 Months-N/A Gender - All Accepting Healthy Volunteers - No

Purpose

Provide patients with serious AdV infection or disease access to treatment with BCV.

Official Title

An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Stanford Investigator(s)

Rajni Agarwal-Hashmi

Eligibility


Inclusion Criteria:

   - Confirmed serious AdV infection based on clinical symptoms and laboratory testing
   showing AdV in the blood or other bodily fluids

   - Able to swallow medication, either tablet or liquid

Exclusion Criteria:

   - Previous dosing with Brincidofovir

   - If female, not pregnant or trying to become pregnant

View More
View Less

Intervention(s):

drug: Brincidofovir

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2022 Stanford Medicine